论文信息 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial - 字舞流文

Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

G. Rosti | J. Cortes | M. Deininger | C. Chuah | J. Lipton | E. Jabbour | M. Talpaz | M. Mauro | P. Rousselot | A. Hochhaus | T. Hughes | J. Apperley | H. de Lavallade | L. Maness | T. Sacha | A. Turkina | E. Lomaia | C. Pavlovsky | B. Moiraghi | J. Mccloskey | Christine Rojas | A. Vorog | Xi-Ling Ren | M. U. Sutton